Is Travere Therapeutics (TVTX) Still Attractive After Recent Share Price Volatility?

Simply Wall St

Tue, February 17, 2026 at 6:11 AM GMT+9 4 min read

In this article:

TVTX

-9.08%

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for FREE.

If you are wondering whether Travere Therapeutics at around US$27.82 still offers value, you are not alone, many investors are asking the same question as the stock has been on the radar of biotech focused portfolios.

The share price has been volatile recently, with a 7.5% decline over the last week, a roughly flat 30 day return of 0.2% decline, a 29.6% year to date decline, but a 21.4% gain over 1 year and 56.1% over 3 years, while sitting slightly lower over 5 years at a 6.0% decline.

These mixed returns have come alongside ongoing interest in Travere Therapeutics as a US focused pharmaceuticals and biotech company. That often means sentiment shifts quickly when new clinical, regulatory, or partnership updates emerge. While this article does not focus on specific recent announcements, that context is important when you think about why the stock has moved the way it has.

On Simply Wall St's valuation checks, Travere Therapeutics scores a 4 out of 6 for being undervalued. This suggests some parts of the market are pricing it below certain fundamental measures. Next we will walk through the usual valuation methods before coming back to a more complete way of thinking about what that score really means.

Find out why Travere Therapeutics’s 21.4% return over the last year is lagging behind its peers.

Approach 1: Travere Therapeutics Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a business might be worth today by projecting its future cash flows and then discounting those back to a single present value figure.

For Travere Therapeutics, the model used is a 2 stage Free Cash Flow to Equity approach based on cash flows in US$. The latest twelve month free cash flow is a loss of about $164.2 million. Analyst inputs and subsequent projections indicate free cash flow of $475.3 million in 2030, with intermediate years such as 2026 and 2027 modeled at $102.3 million and $168.5 million respectively. Beyond the explicit analyst horizon, Simply Wall St extrapolates additional years of free cash flow growth to complete the 2 stage model.

Discounting all those projected cash flows back to today, the model produces an estimated intrinsic value of about $131.15 per share. Compared with a recent share price around $27.82, this suggests the stock is assessed as 78.8% undervalued under these assumptions.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Travere Therapeutics is undervalued by 78.8%. Track this in your watchlist or portfolio, or discover 54 more high quality undervalued stocks.

Story Continues  

TVTX Discounted Cash Flow as at Feb 2026

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Travere Therapeutics.

Approach 2: Travere Therapeutics Price vs Sales

For many profitable companies, price-based multiples like P/S are a quick way to gauge how much you are paying for each unit of revenue. This can be easier to interpret than long-term cash flow models. Investors usually accept higher or lower multiples depending on what they expect for future growth and how risky those cash flows appear, so there is no single “right” number in isolation.

Travere Therapeutics currently trades on a P/S ratio of 5.71x. That sits close to the peer average of 5.37x and below the broader Biotechs industry average P/S of 11.28x. Simply Wall St also calculates a proprietary “Fair Ratio” of 5.63x for Travere. This is the P/S level that might be expected given factors such as its earnings growth profile, industry, profit margins, market cap and specific risks.

This Fair Ratio can be more useful than a simple peer or industry comparison because it adjusts for company-specific characteristics rather than assuming all biotechs should trade on the same multiple. With Travere’s actual P/S of 5.71x sitting very close to the Fair Ratio of 5.63x, the stock screens as broadly in line with what this framework suggests.

Result: ABOUT RIGHT

NasdaqGM:TVTX P/S Ratio as at Feb 2026

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 23 top founder-led companies.

Upgrade Your Decision Making: Choose your Travere Therapeutics Narrative

Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives. Here, you set out a clear story for Travere Therapeutics, link that story to your own forecasts for revenue, earnings and margins, and see the fair value that results from those assumptions, all within Simply Wall St’s Community page that millions of investors use to compare Fair Value to the current share price, react quickly as Narratives update with new news or earnings, and see how a more cautious Travere view anchored to a US$20.00 fair value and a more optimistic view anchored to US$47.00 can both be reasonable depending on how you think FILSPARI, margins and future P/E might play out.

Do you think there’s more to the story for Travere Therapeutics? Head over to our Community to see what others are saying!

NasdaqGM:TVTX 1-Year Stock Price Chart

_ This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._

Companies discussed in this article include TVTX.

Have feedback on this article? Concerned about the content? Get in touch with us directly._ Alternatively, email editorial-team@simplywallst.com_

Terms and Privacy Policy

Privacy Dashboard

More Info